Automated Author ProfilePal, Niyati
Pal, Niyati
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 1.1 (sum of 2 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Rheumatoid arthritis (RA) is aninflammatory disorder, with treatments, particularly cyclooxygenase (COX) inhibitors linked to cardiovascular complications. This study explores Withania somnifera (WS) as potential alternative by targeting microsomal prostaglandin E synthase-1 (mPGES-1). In silico analysis revealed binding affinity of WS phytochemical Withanolide D (−9.8 kcal mol−1) with mPGES-1, and has drug-like properties. Five key targets (STAT1, MIF, MMP12, PAD4, and CDK6) were identified, with strong binding to STAT1 (−10.2 kcal mol−1). In vitro validation using WS roots extract in SW982 cells revealed targeting of NFκB pathway, mPGES-1 and the five genes. Results suggest WS and Withanolide D as alternatives to COX inhibitors.
Authors
- Malik, Swati ;
- Chakraborty, Debolina ;
- Pal, Niyati ;
- Agnihotri, Prachi ;
- Biswas, Sagarika
Rheumatoid arthritis (RA) is aninflammatory disorder, with treatments, particularly cyclooxygenase (COX) inhibitors linked to cardiovascular complications. This study explores Withania somnifera (WS) as potential alternative by targeting microsomal prostaglandin E synthase-1 (mPGES-1). In silico analysis revealed binding affinity of WS phytochemical Withanolide D (−9.8 kcal mol−1) with mPGES-1, and has drug-like properties. Five key targets (STAT1, MIF, MMP12, PAD4, and CDK6) were identified, with strong binding to STAT1 (−10.2 kcal mol−1). In vitro validation using WS roots extract in SW982 cells revealed targeting of NFκB pathway, mPGES-1 and the five genes. Results suggest WS and Withanolide D as alternatives to COX inhibitors.
Authors
- Malik, Swati ;
- Chakraborty, Debolina ;
- Pal, Niyati ;
- Agnihotri, Prachi ;
- Biswas, Sagarika